These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31678470)

  • 21. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 22. [Research progress on the immune checkpoint inhibitors induced cardiotoxicity].
    Lyu SS; Yang YM
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Sep; 47(9):748-751. PubMed ID: 31550849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscular disorder related to immune checkpoint inhibitors: forewarned is forearmed.
    Gallay L; Bourgeois-Vionnet J; Joubert B; Streichenberger N; Hot A
    Neuro Oncol; 2018 May; 20(6):861-862. PubMed ID: 29590458
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.
    Kim ST; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2019 Mar; 15(3):211-213. PubMed ID: 30589372
    [No Abstract]   [Full Text] [Related]  

  • 25. An overview of the toxicities of checkpoint inhibitors in older patients with cancer.
    Alkharabsheh O; Kannarkatt P; Kannarkatt J; Karapetyan L; Laird-Fick HS; Al-Janadi A
    J Geriatr Oncol; 2018 Sep; 9(5):451-458. PubMed ID: 29567089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach.
    Khan Z; Hammer C; Guardino E; Chandler GS; Albert ML
    Genome Med; 2019 Jun; 11(1):39. PubMed ID: 31221204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equibalancing immune-related adverse events and anticancer activity of immune checkpoint inhibitors.
    Seeruttun SR
    Thorac Cancer; 2019 Oct; 10(10):1855-1856. PubMed ID: 31456312
    [No Abstract]   [Full Text] [Related]  

  • 29. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.
    Chren MM; Lasek RJ; Sahay AP; Sands LP
    J Cutan Med Surg; 2001; 5(2):105-10. PubMed ID: 11443481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
    Barroso-Sousa R; Ott PA; Hodi FS; Kaiser UB; Tolaney SM; Min L
    Cancer; 2018 Mar; 124(6):1111-1121. PubMed ID: 29313945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
    Escudier M; Cautela J; Malissen N; Ancedy Y; Orabona M; Pinto J; Monestier S; Grob JJ; Scemama U; Jacquier A; Lalevee N; Barraud J; Peyrol M; Laine M; Bonello L; Paganelli F; Cohen A; Barlesi F; Ederhy S; Thuny F
    Circulation; 2017 Nov; 136(21):2085-2087. PubMed ID: 29158217
    [No Abstract]   [Full Text] [Related]  

  • 32. Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System.
    Raschi E; Antonazzo IC; La Placa M; Ardizzoni A; Poluzzi E; De Ponti F
    Oncologist; 2019 Nov; 24(11):e1228-e1231. PubMed ID: 31387950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
    Furtado VF; Melamud K; Hassan K; Rohatgi S; Buch K
    Clin Imaging; 2020 Jul; 63():35-49. PubMed ID: 32120311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Brahmer JR; Lacchetti C; Thompson JA
    J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.
    Hamamoto Y; Shin N; Hoshino T; Kanai T
    Future Oncol; 2018 Dec; 14(30):3187-3198. PubMed ID: 30188189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
    Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
    Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
    Fessas P; Possamai LA; Clark J; Daniels E; Gudd C; Mullish BH; Alexander JL; Pinato DJ
    Immunology; 2020 Feb; 159(2):167-177. PubMed ID: 31646612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What Have We Got to Lose?
    McNeil CM
    J Clin Oncol; 2016 Dec; 34(36):4443-4444. PubMed ID: 27998220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.